The GSK3β inhibitors TFGF-18 and ISO modulate the gut homeostasis and barrier function to inhibit neuroinflammation and attenuate cognitive impairment by regulating NF-κB, and Nrf2/HO-1 pathways. This evidence concerns the gene HMOX1 and Cognitive impairment.